- Trial Phase
- Pivotal (device; FDA Breakthrough Device designation, De Novo pathway — device equivalent of late-stage/Phase 3)
- Time to Market
- Targeting a US FDA De Novo submission in late Q4 2026 (if pivotal data are positive); FDA review and potential launch would follow no earlier than 2027, with no guarantee of approval.
- Why 8/10
- The next hard, dated binary is the REMAIN-1 Pivotal Cohort (N=315) 6-month topline data expected early Q4 2026 (~2 months out) — a make-or-break readout on Fractyl's lead asset at a pre-revenue company whose valuation rides on Revita — followed by a potential FDA De Novo submission late Q4 2026; that proximity plus near-total concentration warrants an 8.
The single number that moves this stock is the REMAIN-1 Pivotal Cohort 6-month topline result due early Q4 2026 — confirm the exact date in company guidance and position only around that binary. A positive readout likely enables the late-Q4 2026 FDA De Novo submission and re-rates the stock toward analyst targets (mean ~$5.03 vs ~$0.66 price); a miss or weak sham separation would be severe given no revenue and a cash runway that only reaches early 2027.
Price Chart
Executive Summary
Revita is Fractyl Health's (Nasdaq: GUTS) lead asset — a one-time, endoscopically-delivered duodenal mucosal resurfacing device for weight maintenance in people with obesity who discontinue GLP-1 therapies. The FDA granted Breakthrough Device designation on May 12, 2026, and the stock jumped ~23% in one day. Interim one-year data (July 2026) showed Revita retained 81% of prior GLP-1 weight loss vs 48% for sham, but the real test is the REMAIN-1 Pivotal Cohort (N=315) topline 6-month readout expected early Q4 2026, with a potential FDA De Novo submission targeted for late Q4 2026.
How It Works
Revita is a one-time endoscopic procedure, not a pill or injection. A catheter is passed into the first part of the small intestine (duodenum) and ablates (removes/resurfaces) the lining, which regenerates within days. The idea is that resetting this lining changes metabolic signaling so patients keep off weight they lost on GLP-1 drugs (like Ozempic/Wegovy) after they stop taking them — a durable, single-procedure alternative to lifelong injections.
Trial Status
REMAIN-1 Pivotal Cohort (N=315) finished randomization in March 2026; topline 6-month data due early Q4 2026. REMAIN-1 Midpoint Cohort one-year results (reported July 15, 2026) showed a single procedure cut weight regain ~40% vs sham; fully-ablated patients retained 81% of GLP-1-induced weight loss at one year vs 48% with sham, with responder rates of 73–91% against the FDA-mandated 50% performance goal and no device-related serious adverse events. Open-label REVEAL-1 data (June 2026) showed ~78% of prior GLP-1 weight loss maintained at one year.
The Two-Sided Case
Upcoming Catalysts
- REMAIN-1 Pivotal Cohort topline 6-month data — expected early Q4 2026 (the key binary).
- Potential FDA De Novo submission for Revita in post-GLP-1 weight maintenance — targeted late Q4 2026.
- RJVA-001 (AAV gene therapy for type 2 diabetes) first dosing / preliminary data expected H2 2026 (side program).
- Quarterly results and any financing/cash-runway updates (Q3 2026 earnings).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
FRACTYL HEALTH, INC. 8-K GUTS ·Originating report